Bevacizumab compared with Diode Laser in stage 3 posterior retinopathy of prematurity: a 5 year follow-up

Hdl Handle:
http://hdl.handle.net/10147/620777
Title:
Bevacizumab compared with Diode Laser in stage 3 posterior retinopathy of prematurity: a 5 year follow-up
Authors:
O’Keeffe, N; Murphy, J; O’Keeffe, M; Lanigan, B
Publisher:
Irish Medical Journal
Journal:
Irish Medical Journal
Issue Date:
Feb-2016
URI:
http://hdl.handle.net/10147/620777
Abstract:
We conducted a prospective randomized study to compare outcomes of intravitreal Bevacizumab versus diode laser in thirty eyes of fifteen premature babies with zone 1 or posterior zone 2 retinopathy of prematurity (ROP). We recorded complications, regression/reactivation of ROP, visual outcome, refractive error and systemic complications. The Bevacizumab-treated eyes showed rapid regression of the ROP with resolution of plus disease and flattening of the ridge at 48 hours post injection. In 3 Bevacizumab-treated eyes, reactivation occurred and were treated with laser (3 eyes) or a further Bevacizumab injection (1 eye). Of the diode laser treated eyes, one showed progression and was treated with Bevacizumab. At 5-year follow-up, good outcomes were observed in both treatment groups. However, less myopia was found in the Bevacizumab compared with the diode laser treated eyes.
Item Type:
Article
Language:
en
Keywords:
PREMATURE BIRTH; EYE CARE

Full metadata record

DC FieldValue Language
dc.contributor.authorO’Keeffe, Nen
dc.contributor.authorMurphy, Jen
dc.contributor.authorO’Keeffe, Men
dc.contributor.authorLanigan, Ben
dc.date.accessioned2016-09-30T10:56:56Z-
dc.date.available2016-09-30T10:56:56Z-
dc.date.issued2016-02-
dc.identifier.urihttp://hdl.handle.net/10147/620777-
dc.description.abstractWe conducted a prospective randomized study to compare outcomes of intravitreal Bevacizumab versus diode laser in thirty eyes of fifteen premature babies with zone 1 or posterior zone 2 retinopathy of prematurity (ROP). We recorded complications, regression/reactivation of ROP, visual outcome, refractive error and systemic complications. The Bevacizumab-treated eyes showed rapid regression of the ROP with resolution of plus disease and flattening of the ridge at 48 hours post injection. In 3 Bevacizumab-treated eyes, reactivation occurred and were treated with laser (3 eyes) or a further Bevacizumab injection (1 eye). Of the diode laser treated eyes, one showed progression and was treated with Bevacizumab. At 5-year follow-up, good outcomes were observed in both treatment groups. However, less myopia was found in the Bevacizumab compared with the diode laser treated eyes.en
dc.language.isoenen
dc.publisherIrish Medical Journalen
dc.subjectPREMATURE BIRTHen
dc.subjectEYE CAREen
dc.titleBevacizumab compared with Diode Laser in stage 3 posterior retinopathy of prematurity: a 5 year follow-upen
dc.typeArticleen
dc.identifier.journalIrish Medical Journalen
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.